Rifaximin
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Not needed here — I have everything required directly in the evidence pack. Proceeding to generate the report.
Rifaximin: From (No Approved Indication on File) to Oral Candidiasis
One-Sentence Summary
Rifaximin is a rifamycin-class, gut-restricted oral antibiotic; it is not currently marketed in Taiwan and no approved-indication text is on file. The TxGNN model predicts it may be effective for Oral Candidiasis, but this direction is supported by only 1 publication (no clinical trials), and that publication actually reports rifaximin use as a risk factor for resistant Candida infection — not a treatment effect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no Taiwan license/approved-indication text on file (drug is not marketed in Taiwan) |
| Predicted New Indication | Oral Candidiasis |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 (model prediction only; the one literature hit contradicts rather than supports efficacy) |
| Taiwan Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for rifaximin is not available in this evidence pack. Based on general pharmacological knowledge, rifaximin is a non-absorbable, gut-restricted rifamycin derivative that inhibits bacterial DNA-dependent RNA polymerase; it is used clinically (outside Taiwan) for conditions such as hepatic encephalopathy, IBS-D, and traveler's diarrhea. It has no known antifungal or anti-Candida mechanism.
Oral candidiasis is a fungal infection, and there is no established pharmacological pathway by which a gut-selective antibacterial agent would be expected to treat it. The only literature retrieved for this prediction (PMID 34180023) points in the opposite direction: it describes rifaximin use as favouring the emergence of micafungin-resistant Candida infections in allogeneic HSCT recipients, most likely via disruption of gut microbial balance rather than any therapeutic effect. This is evidence of a risk association, not a treatment signal.
Taken together, the TxGNN score likely reflects proximity in the knowledge-graph embedding space (e.g., shared "gut/infection" nodes) rather than a genuine, evidence-backed mechanistic link. This is not a case where absence of trials simply reflects an early-stage but plausible hypothesis — the one piece of available evidence actively argues against the prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34180023 | 2021 | Case report/observational | Annals of Hematology | In allogeneic HSCT recipients, rifaximin use was associated with (favoured) emergence of micafungin-resistant Candida spp. infections — a risk signal, not a treatment finding |
Taiwan Market Information
No authorizations on file. Rifaximin is not currently marketed in Taiwan (0 licenses).
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug–drug interaction data are not yet available in this evidence pack — TFDA package insert retrieval is flagged as a blocking data gap.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on a TxGNN embedding score with no clinical trials and no mechanistic rationale for antifungal activity. The single available publication points against, not toward, therapeutic benefit — rifaximin use was linked to increased resistant-Candida risk rather than efficacy against oral candidiasis. This is insufficient, and directionally unfavorable, evidence to advance.
To proceed, the following is needed:
- TFDA package insert / warnings and contraindications data (currently a blocking data gap)
- Confirmed mechanism-of-action data for rifaximin (currently a data gap)
- In vitro or preclinical data testing rifaximin against Candida species, since no antifungal mechanism is currently established
- Independent re-review of the TxGNN prediction given that the only real-world evidence found contradicts the predicted direction
- If pursued further, safety monitoring should specifically address gut microbiome disruption and secondary fungal infection risk, not just standard antibacterial safety review
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.